REGN

Regeneron Pharmaceuticals

$920.69

-0.29%
Nov 20, 2026
Bobby Quantitative Model
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, and commercializes therapies across eye disease, cardiovascular disease, cancer, inflammation, and immunology, with a marketed portfolio anchored by Eylea/Eylea HD (partnered with Bayer), Dupixent (partnered with Sanofi), Libtayo, Praluent, Kevzara, and the newly launched Lynozyfic for multiple myeloma. It is best characterized as a science-driven platform company rather than a single-asset story: its proprietary VelocImmune and VelociSuite technologies underpin both its commercial antibodies and a deep genetics-driven pipeline, giving it a distinct identity as one of the few large-cap biotechs that pairs blockbuster commercial franchises with industrial-scale internal R&D. The current investor narrative centers on the durability of the Dupixent and Eylea HD growth engines, which drove a striking third-quarter 2026 revenue acceleration, alongside a re-rating debate over whether the stock's sharp autumn rally has already discounted the pipeline optionality from its genetics and oncology programs. Recent coverage following the October 30 print has focused on strong Q3 results, rising R&D investment, and long-term pipeline promise, while partner Bayer's mixed quarterly results keep a watchful eye on the ophthalmology franchise's competitive dynamics.

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Moderna

Moderna

MRNA

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis
United Therapeutics Corp

United Therapeutics Corp

UTHR

Analysis

BobbyInvestment Opinion: Should I buy REGN Today?

Rating: Hold (with a constructive bias toward accumulating on pullbacks). The thesis is that Regeneron is a high-quality, cash-generative biotech whose Q3 2026 revenue acceleration (+36.27% YoY to $5.116 billion) and expanding margins (88.79% gross, 38.09% net) justify a premium franchise valuation, but the 22.75% one-month rally has already captured most of the near-term upside, leaving only +3.1% to the $984.96 average analyst target. The 19 Buy / 9 Hold / 0 Sell consensus (recommendation mean 1.79) confirms the fundamental story is intact while the modest implied upside signals the debate is about entry price and timing, not doubt.

Supporting evidence is strong on every fundamental axis: the 13.49x forward PE on consensus EPS of $92.48 sits below large-cap biotech norms of roughly 20-30x forward earnings, and the 5.63x PS is near the low end of Regeneron's own historical range (which reached 33.2x in Q1 2024). Revenue has accelerated sequentially from $3.605 billion (Q1) to $4.291 billion (Q2) to $5.116 billion (Q3), operating margin climbed from 17.83% to 33.11% to 40.04% over the same quarters, and TTM free cash flow of $3.826 billion is generated against debt-to-equity of just 0.0866. The one valuation caveat is the 3.38 PEG ratio, which suggests the market has already capitalized a multi-year growth runway even as the absolute multiples look undemanding.

The biggest risks that could invalidate the thesis are (1) a Dupixent deceleration, since collaboration revenue of $3.001 billion was roughly 59% of Q3's top line and ties the company to one franchise and one partner (Sanofi); (2) competitive erosion in ophthalmology, underscored by partner Bayer's mixed Q3 results and generic competition flagged as a risk to the Eylea franchise; and (3) multiple compression after the rally, with the stock at 96.3% of its 52-week range and a 26.05% max drawdown already experienced in the past year. This Hold would upgrade to Buy on a pullback into the $850-$900 support zone (improving risk/reward toward the $984.96 average target) or on evidence that collaboration revenue growth is durable across a second consecutive quarter; it would downgrade to Sell if Dupixent collaboration revenue decelerates sequentially or if forward EPS estimates slip materially below the $92.48 consensus. Net verdict: fairly valued to modestly undervalued on absolute multiples relative to history and growth, but fully valued on a near-term risk/reward basis after the rally.

Sign up to view all

REGN 12-Month Price Forecast

Regeneron's fundamentals are unambiguously strong — accelerating revenue, expanding margins, a fortress balance sheet (0.0866 debt-to-equity, $3.826 billion TTM FCF), and a 13.49x forward PE that looks cheap against 36% growth and 88.79% gross margins. The problem is timing: a 22.75% one-month rally has left only +3.1% to the average analyst target, and the 3.38 PEG ratio suggests the market has already paid for the growth runway, so the risk/reward is balanced rather than compelling at $955.47. The 19 Buy / 9 Hold / 0 Sell consensus and 1.79 recommendation mean confirm the bull camp is intact but not broadening, with the debate centered on valuation and entry point rather than fundamental doubt. I would upgrade to bullish on a pullback into the $850-$900 support zone (restoring meaningful upside to the $984.96 target) or on a second consecutive quarter of Dupixent-driven collaboration growth; I would downgrade to bearish if collaboration revenue decelerates sequentially or if forward EPS estimates fall materially below $92.48.

Historical Price
Current Price $920.69
Average Target $1000.00
High Target $1175.00
Low Target $750.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $991.00 and implied upside of +7.6% versus the current price.

Average Target

$991.00

28 analysts

Implied Upside

+7.6%

vs. current price

Analyst Count

28

covering this stock

Price Range

$812 - $1175

Analyst target range

Buy
19 (68%)
Hold
9 (32%)
Sell
0 (0%)

Coverage is deep and constructive, with 27 analysts contributing a distribution of 19 Buy, 9 Hold, and 0 Sell ratings, a consensus recommendation of "buy" and a recommendation mean of 1.79 (where 1.0 is a strong buy). The average target price of $984.96 implies roughly +3.1% upside from the current price of $955.47, a modest gap that reflects how much of the bullish case has already been captured by the recent rally rather than any deterioration in sentiment. The consensus leans clearly bullish on ratings but only mildly positive on price, a combination that typically signals analysts see limited near-term multiple expansion even as they endorse the fundamental story. The target range runs from a low of $812.00 to a high of $1,175.00, a spread of about 44.7% of the low end, which signals meaningful dispersion in assumptions rather than tight conviction. The high target of $1,175.00 (roughly +23% from current levels) likely assumes sustained Dupixent and Eylea HD outperformance, pipeline catalysts from oncology and genetics programs, and possibly further multiple expansion toward the mid-to-high teens on forward earnings; the low target of $812.00 (about -15%) likely prices in margin compression from rising R&D, competitive pressure on the ophthalmology franchise, or slower collaboration revenue growth. Institutional ratings activity from November 2, 2026 shows a stable-to-positive pattern, with Evercore ISI, Canaccord, Guggenheim, Truist, and Cantor Fitzgerald maintaining Buy/Outperform/Overweight stances while Wells Fargo, RBC, Bernstein, Morgan Stanley, and Leerink stayed at Equal Weight/Market Perform, indicating the bull camp is intact but not broadening. The absence of any Sell ratings and the clustering of holds around the market-perform level suggest the debate is about valuation and timing rather than fundamental doubt.

Drowning in data?

Find the real signal!

Bulls vs Bears: REGN Investment Factors

The bull case currently has stronger evidence: 36.27% revenue growth, expanding margins (88.79% gross, 38.09% net), a fortress balance sheet with 0.0866 debt-to-equity, and a 13.49x forward PE that sits below both its own history and large-cap biotech norms. The bear case is primarily about timing and price rather than fundamentals — a 22.75% one-month rally has left only +3.1% upside to the average analyst target, and the PEG of 3.38 suggests growth is already well capitalized. The single most important tension is whether the Q3 acceleration in Dupixent and Eylea HD is durable or a one-quarter step-change; if collaboration revenue keeps compounding at this pace the forward multiple is too low, but if it decelerates the stock's near-52-week-high positioning leaves little cushion. With zero Sell ratings and a 1.79 recommendation mean, the debate is about valuation and entry point, not fundamental doubt.

Bullish

  • Revenue re-accelerating at 36% YoY: Q3 2026 revenue hit $5.116 billion, up 36.27% from $3.754 billion in Q3 2025, and the sequential climb from $3.605 billion (Q1) to $4.291 billion (Q2) to $5.116 billion (Q3) shows acceleration, not stabilization. This is a materially more bullish read than the flat-to-modest growth implied by earlier quarters.
  • Margins expanding sharply on operating leverage: Gross margin rose to 88.79% in Q3 from 86.56% in Q2 and 81.43% in Q1, while net margin jumped to 38.09% from 30.23% and 20.17% over the same sequence. Operating margin reached 40.04% even as R&D climbed to $1.816 billion, proving the company can fund a larger pipeline without sacrificing profitability.
  • Valuation undemanding versus own history: The 17.92x trailing PE and 5.63x PS sit in the middle-to-lower portion of Regeneron's multi-year band, which ranged from 7.5x to 36.2x on earnings and reached 33.2x on sales in Q1 2024. The 13.49x forward PE implies roughly 25% multiple compression on consensus EPS of $92.48, so the stock is not priced for perfection despite its rally.
  • Fortress balance sheet funds R&D internally: Debt-to-equity is just 0.0866, the current ratio is 4.13, and TTM free cash flow is $3.826 billion, with Q3 FCF of $1.483 billion on $1.783 billion operating cash flow against only $300 million capex. Regeneron can expand R&D and buy back stock ($399.7 million in Q3) without external financing, a key differentiator versus cash-burning peers.

Bearish

  • Rally has captured most of the upside: The stock is up 22.75% in the past month and 37.48% over the year, trading at 96.3% of its 52-week range ($591.52 low to $991.73 high) and just 3.7% below the high. The average analyst target of $984.96 implies only +3.1% upside from $955.47, signaling limited near-term multiple expansion even among bulls.
  • PEG of 3.38 flags growth-adjusted richness: While the forward PE of 13.49x looks cheap, the PEG ratio of 3.38 is the one metric arguing the stock is not cheap on a growth-adjusted basis. The market may already be capitalizing a multi-year growth runway, leaving little room for execution slippage.
  • Dupixent collaboration concentration: Collaboration revenue, largely Dupixent profit-sharing with Sanofi, was $3.001 billion of Q3's $5.116 billion, making it the largest single driver and tying Regeneron's fortunes closely to one immunology franchise and one partner. Any Dupixent deceleration or Sanofi relationship friction would hit the largest revenue line directly.
  • Ophthalmology franchise competitive pressure: Partner Bayer's mixed Q3 results, with generic competition flagged as a risk, keep a watchful eye on the Eylea/Eylea HD franchise. Competitive dynamics in ophthalmology represent a direct threat to a core commercial pillar as the stock trades near its highs.

REGN Technical Analysis

Regeneron is in a powerful, sustained uptrend, with the stock up 37.48% over the past year and trading at roughly 96.3% of its 52-week range (52-week low of $591.52 versus high of $991.73, against a current price of $955.47). That positioning near the top of the annual range signals strong momentum rather than a value setup, though it also means the stock is extended and vulnerable to profit-taking on any disappointment. The 26.05% maximum drawdown over the period shows the trend has not been linear, but the recovery has been decisive, with price now just 3.7% below the 52-week high. Short-term momentum is accelerating sharply: the stock is up 22.75% in the past month and 18.92% over three months, both far ahead of the 37.48% one-year gain's implied pace and consistent with a step-change re-rating rather than a gradual grind higher. This acceleration is corroborated by relative strength, with the one-month relative strength versus SPY at 25.01 points and the six-month figure at 34.71 points, meaning Regeneron has massively outperformed a market that itself fell 2.26% over the past month and 2.83% over three months. The absence of a conflicting short-term versus long-term signal (both point up) argues against mean reversion and instead suggests trend continuation, though the velocity of the move raises the odds of a consolidation phase. Key technical support sits at the 52-week low of $591.52, with the more relevant near-term floor likely in the $900-$920 zone established during the early-November pullback from the $973.36 intraday peak; resistance is the 52-week high of $991.73, and a clean breakout above that level would confirm the multi-month uptrend and likely invite momentum-driven flows. A breakdown below $900 would signal the post-earnings gap is fading, while a loss of $591.52 would invalidate the entire annual uptrend. Notably, the reported beta of 0.095 implies very low sensitivity to broad market moves, which is unusual for a large-cap biotech and suggests the stock's risk is idiosyncratic (pipeline, drug pricing, partner dynamics) rather than market-driven, an important consideration for position sizing and portfolio hedging.

Beta

0.10

0.10x market volatility

Max Drawdown

-26.1%

Largest decline past year

52-Week Range

$592-$992

Price range past year

Annual Return

+24.9%

Cumulative gain past year

PeriodREGN ReturnS&P 500
1m+14.3%-9.7%
3m+10.4%-9.9%
6m+44.1%-7.5%
1y+24.9%+4.7%
ytd+18.6%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

REGN Fundamental Analysis

Revenue is inflecting sharply upward: Q3 2026 revenue reached $5.116 billion, up 36.27% year over year from $3.754 billion in Q3 2025, and the sequential trajectory is equally strong, rising from $3.605 billion in Q1 to $4.291 billion in Q2 to $5.116 billion in Q3. The segment mix shows collaboration revenue (largely Dupixent profit-sharing with Sanofi) at $3.001 billion, product revenue at $1.805 billion, and other product/service revenue at $310 million, meaning the collaboration line is the largest single driver and ties Regeneron's fortunes closely to Dupixent's immunology momentum. This acceleration, coming after a softer Q1 ($3.605 billion) and Q4 2025 ($3.884 billion), implies the growth engine has re-accelerated rather than merely stabilized, a materially more bullish read for the investment case than the flat-to-modest growth implied by earlier quarters. Profitability is robust and expanding: Q3 2026 net income was $1.949 billion with a gross margin of 88.79%, up from 86.56% in Q2 and 81.43% in Q1, and net margin improved to 38.09% from 30.23% and 20.17% over the same sequence. Operating margin followed the same path, rising to 40.04% in Q3 from 33.11% in Q2 and 17.83% in Q1, while R&D spending climbed to $1.816 billion from $1.635 billion and $1.645 billion, showing the company is funding a larger pipeline without sacrificing margin. The 85.35% trailing gross margin and 24.95% operating margin are consistent with a best-in-class large-cap biotech, and the improving trend suggests operating leverage is now working in shareholders' favor. The balance sheet is fortress-like: debt-to-equity is just 0.0866, the current ratio is 4.13, and TTM free cash flow is $3.826 billion, with Q3 free cash flow of $1.483 billion on operating cash flow of $1.783 billion against capex of $300 million. ROE of 14.41% and ROA of 7.59% are healthy for the sector, and the company is returning capital via $399.7 million of Q3 buybacks and a small dividend (payout ratio 8.22%, yield 0.46%), while still growing cash to $3.672 billion. The low leverage and strong internal cash generation mean Regeneron can fund its R&D expansion without external financing, a key differentiator versus cash-burning peers.

Quarterly Revenue

$5.1B

2026-09

Revenue YoY Growth

+36.3%

YoY Comparison

Gross Margin

88.8%

Latest Quarter

Free Cash Flow

$3.8B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Collaboration Revenue
Product and Service, Other
Product

Open an Account, get $2 TSLA now!

Valuation Analysis: Is REGN Overvalued?

Because Regeneron is solidly profitable (Q3 net income of $1.949 billion), the PE ratio is the appropriate primary metric, and the trailing PE of 17.92x against a forward PE of 13.49x implies the market expects meaningful earnings growth over the next twelve months. That gap (roughly 25% compression in the multiple) is consistent with consensus EPS estimates averaging $92.48 for the forward period, and it suggests the stock is not priced for perfection on an earnings basis despite its sharp price rally. On a price-to-sales basis, the 5.63x PS and 5.28x EV/Sales look moderate for a biotech with 36% revenue growth, while the 13.81x EV/EBITDA and 2.58x price-to-book are reasonable for a high-margin, low-leverage franchise. Peer comparison is constrained because the provided valuation dataset does not include explicit industry-average multiples; however, relative to large-cap biotechnology norms (where premium franchises often trade at 20-30x forward earnings and 6-10x sales), Regeneron's 13.49x forward PE and 5.63x PS appear to sit at a discount rather than a premium, a spread that seems unjustified given its 88.79% gross margin, 38.09% net margin, and 36.27% revenue growth. The PEG ratio of 3.38 is the one metric that argues the stock is not cheap on a growth-adjusted basis, suggesting the market may already be capitalizing a multi-year growth runway. Historical context is instructive: Regeneron's own PE has ranged from roughly 7.5x (Q4 2021) to 36.2x (Q1 2024), with recent readings of 9.89x in Q3 2026 and 12.38x in Q2 2026, meaning the current 17.92x trailing PE sits in the middle-to-lower portion of its multi-year band rather than at an extreme. The PS ratio tells a similar story, at 5.63x versus historical readings that reached 33.2x in Q1 2024 and 30.5x in Q3 2024, so on a sales basis the stock is near the low end of its own history. Taken together, the valuation looks undemanding relative to both its own history and its growth and margin profile, with the main caveat being that the forward multiple's compression depends on consensus EPS delivery.

PE

17.9x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 8x~28x

vs. Industry Avg

29.3x

Industry PE ~29.3x*

EV/EBITDA

13.8x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on revenue concentration and the durability of the Q3 inflection. Collaboration revenue of $3.001 billion — largely Dupixent profit-sharing with Sanofi — represented roughly 59% of Q3's $5.116 billion, so a single immunology franchise and a single partner drive the majority of the top line. R&D spending is climbing ($1.816 billion in Q3 versus $1.635 billion in Q2 and $1.645 billion in Q1), and while margins currently absorb it, a revenue miss would expose the fixed-cost base quickly. Earnings volatility is real: quarterly diluted EPS swung from $6.75 (Q1) to $12.20 (Q2) to $18.45 (Q3), and the forward PE of 13.49x depends on consensus EPS of $92.48 being delivered, leaving little tolerance for slippage. The low debt-to-equity of 0.0866 and $3.826 billion TTM free cash flow mitigate balance-sheet risk but do not offset franchise concentration. Market and competitive risks are dominated by valuation compression after the rally. The stock trades at 96.3% of its 52-week range and is up 22.75% in a month against a market that fell 2.26%, with one-month relative strength of 25.01 points — a setup vulnerable to profit-taking. Bayer's mixed Q3 results and generic competition in ophthalmology threaten the Eylea franchise, while the PEG of 3.38 means any growth deceleration would likely trigger multiple contraction. The reported beta of 0.095 implies very low market sensitivity, so risk is idiosyncratic — pipeline readouts, drug pricing policy, and partner dynamics — rather than macro-driven, which matters for position sizing since broad-market hedging offers little protection. The worst-case scenario is a Dupixent growth stall combined with Eylea HD competitive erosion and a pipeline disappointment, compressing the forward multiple toward the low end of its historical band. From the current $955.47, a retest of the 52-week low of $591.52 would mean roughly -38%, while the analyst low target of $812.00 implies about -15%. A more realistic adverse path — a fade back to the $750-$800 area seen in September-October 2026 — represents a -16% to -21% drawdown, consistent with the 26.05% maximum drawdown already experienced over the past year.

FAQ

The most severe risk is franchise concentration: collaboration revenue of $3.001 billion, largely Dupixent profit-sharing with Sanofi, was roughly 59% of Q3's $5.116 billion, so a single immunology drug and a single partner drive the majority of the top line. Second is competitive erosion in ophthalmology, where partner Bayer's mixed Q3 results flagged generic competition against the Eylea/Eylea HD franchise, a core commercial pillar. Third is valuation and timing risk — the stock is up 22.75% in a month, sits at 96.3% of its 52-week range, and has already endured a 26.05% maximum drawdown in the past year, so profit-taking could be sharp, with the analyst low target of $812.00 implying about -15% and the 52-week low of $591.52 implying roughly -38%. Fourth is earnings-delivery risk: the 13.49x forward PE depends on $92.48 consensus EPS, and quarterly diluted EPS has swung from $6.75 (Q1) to $12.20 (Q2) to $18.45 (Q3), so any slippage would likely trigger multiple compression. Notably, the 0.095 beta means broad-market hedging offers little protection, since the risk is idiosyncratic.

The 12-month forecast splits into three scenarios: a base case at $950-$1,050 with 55% probability, a bull case at $1,100-$1,175 with 20% probability, and a bear case at $750-$812 with 25% probability. The base case assumes revenue growth moderates from the Q3 spike while margins hold in the high-30s and the stock grinds toward the $984.96 average analyst target, with the forward PE staying in the low-to-mid teens. The bull case requires Dupixent and Eylea HD to sustain the Q3 step-change plus at least one positive late-stage pipeline readout, driving the stock toward the $1,175.00 high target (+23%). The bear case assumes Dupixent growth stalls, Eylea HD faces accelerating generic pressure, and rising R&D fails to produce catalysts, pulling the stock toward the $812.00 low target (-15%) and potentially the $750-$800 area. The base case is most likely, and its key assumption is that collaboration revenue growth remains durable across a second consecutive quarter.

REGN looks fairly valued to modestly undervalued on absolute multiples but fully valued on a near-term basis after its rally. The trailing PE of 17.92x and forward PE of 13.49x sit in the middle-to-lower portion of Regeneron's own multi-year band, which has ranged from about 7.5x to 36.2x, and the 5.63x PS is far below the 33.2x reached in Q1 2024. Against large-cap biotech peers that often trade at 20-30x forward earnings, a 13.49x multiple on $92.48 consensus EPS implies the market is paying a discount despite 36% growth and 88.79% gross margins. The counterweight is the 3.38 PEG ratio, which says the market has already paid up on a growth-adjusted basis, and the fact that only +3.1% upside remains to the $984.96 average target. In short, the valuation implies the market expects solid but not spectacular execution — it is not priced for perfection, but it is no longer a bargain after a 37.48% one-year gain.

On a risk/reward basis REGN is a reasonable but not compelling buy at $955.47, because the fundamentals are excellent while the entry point is stretched. The bull case is anchored by 36.27% YoY revenue growth to $5.116 billion, an 88.79% gross margin, 40.04% operating margin, $3.826 billion TTM free cash flow, and a 13.49x forward PE on $92.48 consensus EPS — cheap against large-cap biotech norms of roughly 20-30x. The catch is that the stock has rallied 22.75% in a month and trades at 96.3% of its 52-week range, leaving only +3.1% to the $984.96 average analyst target, with the 3.38 PEG ratio suggesting growth is already capitalized. The biggest downside risk is a Dupixent collaboration slowdown, since that line was about 59% of Q3 revenue, and the analyst low target of $812.00 implies roughly -15%. It is a good buy for long-term investors comfortable with a partial position now and adding on a pullback toward $850-$900, but less attractive for anyone chasing the recent momentum.

REGN is better suited to long-term holding than short-term trading, though its low beta of 0.095 makes it an unusual momentum vehicle. The fundamentals support a multi-year hold: 36.27% revenue growth, 88.79% gross margin, $3.826 billion TTM free cash flow, debt-to-equity of 0.0866, and a 13.49x forward PE on $92.48 consensus EPS give earnings visibility that most biotechs lack. The dividend is negligible (0.46% yield, 8.22% payout), so total return depends on earnings growth and multiple re-rating rather than income. Short-term traders face a difficult setup: the stock is up 22.75% in a month, sits at 96.3% of its 52-week range, and has a 26.05% maximum drawdown history, so near-term upside to the $984.96 average target is only +3.1%. A sensible minimum holding period is 12-18 months, long enough to capture at least two more quarterly reports confirming Dupixent durability and any pipeline readouts, with position sizing that accounts for idiosyncratic rather than market risk.